Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Shenzhen New Industries Biomedical Engineering Co Ltd
Cash from Operating Activities
Shenzhen New Industries Biomedical Engineering Co Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Cash from Operating Activities
¥1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Cash from Operating Activities
¥2.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
Cash from Operating Activities
¥780.7m
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Cash from Operating Activities
¥1.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Winner Medical Co Ltd
SZSE:300888
|
Cash from Operating Activities
¥3B
|
CAGR 3-Years
71%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Cash from Operating Activities
-¥3.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Shenzhen New Industries Biomedical Engineering Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.4B
CNY
Based on the financial report for Dec 31, 2023, Shenzhen New Industries Biomedical Engineering Co Ltd's Cash from Operating Activities amounts to 1.4B CNY.
What is Shenzhen New Industries Biomedical Engineering Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
15%
Over the last year, the Cash from Operating Activities growth was 47%. The average annual Cash from Operating Activities growth rates for Shenzhen New Industries Biomedical Engineering Co Ltd have been 13% over the past three years , 15% over the past five years .